Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 80.22
IDRA's Cash to Debt is ranked higher than
53% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. IDRA: 80.22 )
Ranked among companies with meaningful Cash to Debt only.
IDRA' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 1071.91 Max: No Debt
Current: 80.22
Equity to Asset 0.94
IDRA's Equity to Asset is ranked higher than
92% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. IDRA: 0.94 )
Ranked among companies with meaningful Equity to Asset only.
IDRA' s Equity to Asset Range Over the Past 10 Years
Min: -1.57  Med: 0.57 Max: 0.94
Current: 0.94
-1.57
0.94
F-Score: 4
Z-Score: 13.69
M-Score: 18.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -79822.95
IDRA's Operating margin (%) is ranked lower than
98% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. IDRA: -79822.95 )
Ranked among companies with meaningful Operating margin (%) only.
IDRA' s Operating margin (%) Range Over the Past 10 Years
Min: -53084.93  Med: -622.17 Max: 21.4
Current: -79822.95
-53084.93
21.4
Net-margin (%) -79480.33
IDRA's Net-margin (%) is ranked lower than
99% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. IDRA: -79480.33 )
Ranked among companies with meaningful Net-margin (%) only.
IDRA' s Net-margin (%) Range Over the Past 10 Years
Min: -52934.25  Med: -619.07 Max: 21.86
Current: -79480.33
-52934.25
21.86
ROE (%) -60.03
IDRA's ROE (%) is ranked lower than
68% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. IDRA: -60.03 )
Ranked among companies with meaningful ROE (%) only.
IDRA' s ROE (%) Range Over the Past 10 Years
Min: -352.71  Med: -126.38 Max: 27.3
Current: -60.03
-352.71
27.3
ROA (%) -54.93
IDRA's ROA (%) is ranked lower than
72% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. IDRA: -54.93 )
Ranked among companies with meaningful ROA (%) only.
IDRA' s ROA (%) Range Over the Past 10 Years
Min: -108.01  Med: -70.76 Max: 14.1
Current: -54.93
-108.01
14.1
ROC (Joel Greenblatt) (%) -3554.27
IDRA's ROC (Joel Greenblatt) (%) is ranked lower than
77% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. IDRA: -3554.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IDRA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -11798.05  Med: -3259.66 Max: 467.46
Current: -3554.27
-11798.05
467.46
EBITDA Growth (3Y)(%) -17.60
IDRA's EBITDA Growth (3Y)(%) is ranked lower than
67% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. IDRA: -17.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IDRA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -69.8  Med: -16.75 Max: 4.8
Current: -17.6
-69.8
4.8
EPS Growth (3Y)(%) -22.70
IDRA's EPS Growth (3Y)(%) is ranked lower than
72% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. IDRA: -22.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IDRA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -62.7  Med: -21.70 Max: 4.8
Current: -22.7
-62.7
4.8
» IDRA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

IDRA Guru Trades in Q1 2015

Paul Tudor Jones 22,100 sh (New)
Steven Cohen 137,087 sh (New)
» More
Q2 2015

IDRA Guru Trades in Q2 2015

Paul Tudor Jones Sold Out
Steven Cohen 113,200 sh (-17.42%)
» More
Q3 2015

IDRA Guru Trades in Q3 2015

Paul Tudor Jones 18,993 sh (New)
Steven Cohen 670,600 sh (+492.40%)
» More
Q4 2015

IDRA Guru Trades in Q4 2015

Jim Simons 20,050 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with IDRA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.12
IDRA's P/B is ranked higher than
61% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.89 vs. IDRA: 2.12 )
Ranked among companies with meaningful P/B only.
IDRA' s P/B Range Over the Past 10 Years
Min: 0.83  Med: 5.49 Max: 548
Current: 2.12
0.83
548
P/S 2919.77
IDRA's P/S is ranked lower than
99.99% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.77 vs. IDRA: 2919.77 )
Ranked among companies with meaningful P/S only.
IDRA' s P/S Range Over the Past 10 Years
Min: 0  Med: 26.84 Max: 2972.53
Current: 2919.77
0
2972.53
Current Ratio 11.98
IDRA's Current Ratio is ranked higher than
80% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. IDRA: 11.98 )
Ranked among companies with meaningful Current Ratio only.
IDRA' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 4.15 Max: 18.76
Current: 11.98
0.02
18.76
Quick Ratio 11.98
IDRA's Quick Ratio is ranked higher than
81% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. IDRA: 11.98 )
Ranked among companies with meaningful Quick Ratio only.
IDRA' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 4.15 Max: 18.76
Current: 11.98
0.02
18.76

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.32
IDRA's Price/Net Cash is ranked higher than
84% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: 5.54 vs. IDRA: 3.32 )
Ranked among companies with meaningful Price/Net Cash only.
IDRA' s Price/Net Cash Range Over the Past 10 Years
Min: 2.02  Med: 6.70 Max: 141.33
Current: 3.32
2.02
141.33
Price/Net Current Asset Value 3.19
IDRA's Price/Net Current Asset Value is ranked higher than
85% of the 893 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. IDRA: 3.19 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
IDRA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.95  Med: 6.44 Max: 56.96
Current: 3.19
1.95
56.96
Price/Tangible Book 2.13
IDRA's Price/Tangible Book is ranked higher than
81% of the 1047 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. IDRA: 2.13 )
Ranked among companies with meaningful Price/Tangible Book only.
IDRA' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.9  Med: 6.67 Max: 413
Current: 2.13
1.9
413
Earnings Yield (Greenblatt) (%) -36.79
IDRA's Earnings Yield (Greenblatt) (%) is ranked lower than
79% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. IDRA: -36.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IDRA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -37.43  Med: 5.70 Max: 164845.8
Current: -36.79
-37.43
164845.8

More Statistics

Revenue(Mil) $0
EPS $ -0.47
Beta2.37
Short Percentage of Float18.49%
52-Week Range $1.50 - 5.24
Shares Outstanding(Mil)118.35

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 0 1 1 1
EPS($) -0.43 -0.40 -0.44 -0.47
EPS without NRI($) -0.43 -0.40 -0.44 -0.47

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HXXA.Germany,
Idera Pharmaceuticals Inc was incorporated in Delaware on May 25, 1989. The Company is a clinical stage biotechnology company. The Company is engaged in the discovery, development and commercialization of novel therapeutics for oncology and rare diseases. The Company uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates including nucleic acid therapeutics that target biologic pathways implicated in disease processes. The Company first platform focuses on inhibiting over-activation of Toll-like receptors (TLRs) and the second is its gene silencing oligonucleotides (GSOs) platform. The Company TLR antagonist drug candidates are IMO-8400 and IMO-9200, which are both antagonists of TLR7, TLR8 and TLR9. The Company also has created compounds that are agonists of TLR3, TLR7, TLR8 and TLR9. Its TLR agonist drug candidates are IMO-2055 and IMO-2125, which are both agonists of TLR9. The Company's drug candidates include IMO-8400 an novel synthetic oligonucleotide antagonist of TLR7, TLR8, and TLR9. It is developing IMO-8400 for the treatment of certain genetically defined forms of B-cell lymphoma and for the treatment of rare diseases. It is also conducting a Phase 1 clinical trial of IMO-9200 in healthy subjects, as well as additional preclinical studies of IMO-9200 for a selected autoimmune disease. The Company relies upon third parties to produce material for nonclinical and clinical testing purposes. The Company's competitors include Dynavax, InDex Pharmaceuticals AB, Mologen AG, BioLineRx Ltd., Innate Immunotherapeutics Ltd., VentiRx Pharmaceuticals Inc., Telormedix S.A., Gilead Sciences Inc., GlaxoSmithKline plc, AstraZeneca plc and Hoffmann-La Roch. The testing, manufacturing, labeling, advertising, promotion, export, and marketing of its drug candidates are subject to regulation by governmental authorities in Europe, the United States, and elsewhere throughout the world.
» More Articles for IDRA

Headlines

Articles On GuruFocus.com
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
Insiders Are Buying Idera Pharmaceuticals Sep 19 2013 

More From Other Websites
Propanc Health Group, Top Our List for Investor Potential in Biotech Feb 12 2016
5 Stocks Ready for Breakouts Jan 29 2016
IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 11 2016
IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jan 08 2016
Biotechnology Stocks Review -- Idera Pharma, Vital Therapies, Lion Biotechnologies, and Cara... Jan 08 2016
IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jan 06 2016
Idera Pharmaceuticals Announces Appointment of Dr. Maxine Gowen to Its Board of Directors Jan 06 2016
Coverage initiated on Idera Pharma by Wedbush Jan 06 2016
Idera to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 05 2016
Healthcare Sector Equities in Motion -- Idera Pharma, Bellicum Pharma, OraSure Technologies, and... Dec 22 2015
Idera Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 21 2015
Idera Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : December 17,... Dec 17 2015
Idera Pharmaceuticals Inc (IDRA): Are Hedge Funds Right About This Stock? Dec 14 2015
Idera Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Trial of Intra-tumoral IMO-2125 in... Dec 14 2015
5 Key BioPharma Movers That Cannot Be Ignored Dec 12 2015
IDERA PHARMACEUTICALS, INC. Financials Dec 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK